Regentis Biomaterials Ltd. (RGNT)
Regentis Biomaterials will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$10.00 - $12.00
Shares Offered
909,090
Deal Size
$10.00M
Company Description
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients.
Our current efforts are focused on orthopedic treatments using our Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue.
Our lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
GelrinC was approved as a device, with a Conformité Européene, or CE, mark in Europe in 2017. We plan to identify strategic partners in Europe to bring our product to market.
Regentis Biomaterials Ltd.
| Country | Israel |
| Founded | 2004 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Eli Hazum |
Contact Details
Address: 60 Medinat Hayehudim Herzliya, 4676652 Israel | |
| Phone | +972 (9) 960-1917 |
| Website | regentis.co.il |
Stock Details
| Ticker Symbol | RGNT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001912966 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ehud Geller | Director, Chairman |
| Mr. Jeff Dykan | Director |
| Mr. Keith Valentine | Director(1) |
| Dr. Eli Hazum | Chief Executive Officer |
| Mr. Arie Gordashnikov | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2025 | F-1 | Registration statement for certain foreign private issuers |
| Feb 12, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 27, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 24, 2025 | DRS | [Cover] Draft Registration Statement |
| Nov 21, 2024 | DRS | [Cover] Draft Registration Statement |
| Nov 21, 2024 | RW | Filing |
| Dec 19, 2022 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 7, 2022 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Nov 4, 2022 | F-1 | Registration statement for certain foreign private issuers |
| Sep 23, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |